Covington & Burling, Latham Lead UCB's $2B Ra Pharma Buy
Belgium's UCB, advised by Covington & Burling, unveiled plans Thursday to snap up Latham & Watkins-led clinical stage biotech company Ra Pharma in a $2.1 billion deal, as UCB looks to...To view the full article, register now.
Already a subscriber? Click here to view full article